Drug interactions and clinical pharmacokinetics
- PMID: 797504
- DOI: 10.2165/00003088-197601050-00003
Drug interactions and clinical pharmacokinetics
Abstract
Some drugs influence the gastro-intestinal absorption, distribution , metabolism or renal excretion of other drugs, i.e., processes involved in pharmacokinetic interactions. The clinical consequences of pharmacokinetic drug-drug interactions will be either an increase or a decrease in known therapeutic or toxic effects of the interacting drug. In order to evaluate the importance of drug interaction affecting gastro-intestinal absorption, it is necessary to distinguish between interactions which alter the rate of absorption of another drug and those which alter the amount of drug absorbed. Many drugs displace other drugs from their protein binding sites in vitro. This may cause an increase in the pharmacological effect of the displaced drug. However, much discrepancy exists between in vitro findings. In some cases, the enhanced effect only seems to be a temporary phenomenon. The degree of protein binding and the size of apparent volume of distribution (Vd) must also be taken into consideration. Perhaps the importance of interaction involving protein binding has been overemphasized. Barbiturates, glutethimide, rifampicin and phenytoin increase the rate of drug metabolism in man. The most important interactions reported are between oral anti-coagulants and barbiturates. After withdrawal of these hepatic microsomal enzyme inducing drugs, it takes 2 to 3 weeks before the rate of drug metabolism reaches the pretreatment level. In this period, risk of haemorrhage exists. Induction seems to be dose-dependent, but not all persons are inducible. Many drugs compete for the drug metabolising enzyme system in the liver and consequently some drugs inhibit the biotransformation of other drugs. The time course of these interactions depends on the pharmacokinetic properties of the drug involved, and these interactions also seem to be dose-dependent. The most important of such interactions, clinically involved the oral sulphonylurea hypoglycaemic drugs and the antiepilepic drug phenytoin. Drugs are eliminated by urinary excretion through three mechanisms: glomerular filtration, tubular reabsorption, and active tubular secretion. The most important interactions seem to be those involving competition for tubular secretion.
Similar articles
-
Pharmacokinetic drug interactions with phenytoin (Part I).Clin Pharmacokinet. 1990 Jan;18(1):37-60. doi: 10.2165/00003088-199018010-00003. Clin Pharmacokinet. 1990. PMID: 2178849 Review.
-
Pharmacokinetics in the elderly.Clin Pharmacokinet. 1976;1(4):280-96. doi: 10.2165/00003088-197601040-00003. Clin Pharmacokinet. 1976. PMID: 797500 Review.
-
Drug kinetics and alcohol ingestion.Clin Pharmacokinet. 1978 Nov-Dec;3(6):440-52. doi: 10.2165/00003088-197803060-00002. Clin Pharmacokinet. 1978. PMID: 31257 Review.
-
[Drug interactions].Pharmazie. 1979 Apr;34(4):260-3. Pharmazie. 1979. PMID: 482341 German. No abstract available.
-
Pharmacokinetic approaches to the study of drug interactions.Ann N Y Acad Sci. 1976;281:24-39. doi: 10.1111/j.1749-6632.1976.tb27917.x. Ann N Y Acad Sci. 1976. PMID: 798525 Review. No abstract available.
Cited by
-
Drug metabolites in renal failure: pharmacokinetic and clinical implications.Clin Pharmacokinet. 1981 Sep-Oct;6(5):329-45. doi: 10.2165/00003088-198106050-00001. Clin Pharmacokinet. 1981. PMID: 7037261 Review. No abstract available.
-
Diseases and drug protein binding.Clin Pharmacokinet. 1978 Mar-Apr;3(2):144-54. doi: 10.2165/00003088-197803020-00004. Clin Pharmacokinet. 1978. PMID: 25156 Review.
-
Protein binding drug displacement interactions fact or fiction?Clin Pharmacokinet. 1989 Feb;16(2):65-73. doi: 10.2165/00003088-198916020-00001. Clin Pharmacokinet. 1989. PMID: 2656044 Review. No abstract available.
-
Drug interactions with cimetidine.Clin Pharmacokinet. 1982 Jan-Feb;7(1):23-41. doi: 10.2165/00003088-198207010-00002. Clin Pharmacokinet. 1982. PMID: 7042171 Review. No abstract available.
-
The Impact of Baohuoside I on the Metabolism of Tofacitinib in Rats.Drug Des Devel Ther. 2024 Mar 25;18:931-939. doi: 10.2147/DDDT.S436549. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 38560524 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources